Whilst the cell and gene therapy (CGT) sector has greatly expanded, patient access to these treatments remain poor. Delara Motlagh, PhD, MS, EMBA, Terumo Blood and Cell Technologies, Lakewood, CO, describes strategies to improve patient access to cell and gene therapies. Dr Motlagh emphasizes the need to improve reimbursement pathways, which will have to take into account the curative nature of these treatments. She additionally highlights current accessibility problems patients face, as these therapies can only be typically administered from a select number of medical centers or academic institutions. This interview took place at Advanced Therapies Week 2022.
Delara Motlagh, PhD, MS, EMBA, is an employee of Terumo Blood and Cell Technologies.